Shanghai Junshi Biosciences' (HKG:1877, SHA:688180) attributable loss narrowed to 1.28 billion yuan in 2024 from 2.28 billion yuan in 2023, according to a Thursday filing with the Hong Kong Exchange.
Loss per share at the drug company fell to 1.30 yuan from 2.32 yuan in the previous year.
Total operating income grew 30% to 1.94 billion yuan from 1.50 billion yuan a year earlier.